Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): This work was supported by the European Research Area Network on Cardiovascular Diseases 807 (2016T092) and Hartstichting (2019T104) Background/Introduction/Purpose Cardiotoxicity continues to be a significant factor in drug withdrawal, partly due to the unpredictable nature of animal models. Moreover, the limitation of cancer treatment arises from the potential risk of cardiotoxicity. Identifying patients at risk of developing heart symptoms after therapy will strongly contribute to improved treatment possibilities. Cardiomyocytes derived from human pluripotent stem cells (hPSCs) represent an inexhaustible cell reservoir and hold the potential to provide personalized solutions to address this issue. However, conventional 2D cultures have several limitations, such as tissue complexity and the difficulty to apply repeated dose treatments. Methods Therefore, we developed an engineered heart tissue (EHT) platform to predict functional aspects of cardiotoxicity. We evaluated the effect of several anti-cancer drugs on cardiomyocyte contractility after repetitive treatment and quantified force of contraction and contraction kinetics. However, these traditional EHTs lack the complexity of diverse cell types. Thus, in a next step, we generated an innovative and user-friendly Heart-on-Chip (HoC) model from hPSC-derived cardiomyocytes, endothelial and smooth muscle cells. Under flow, these miniaturized micro-EHTs (μEHTs) self-organize into a cardiomyocyte core surrounded by an endothelial barrier layer mimicking the cardiomyocyte-endothelial interface as observed in vivo. Results Our versatile drug screening systems permit following individual tissues over time. We therefore treated EHTs with DMSO or 1 μM Doxorubicin for 24 hours and monitored tissue contraction force over a time course of 28 days. Doxorubicin treatment initially caused a drop of force, but demonstrated a recovery of force and kinetics 10 days after treatment. To recapitulate a clinically relevant intermittent treatment regime, a second treatment of 1 μM Doxorubicin was administered 21 days after the first dose and showed a similar decrease in contraction force compared with the first exposure to the drug. μEHTs cultured under flow exhibit improved contractile performance and conduction velocity when compared to static culture conditions. Importantly, the presence of an endothelial barrier delayed the cardiotoxic effect of drugs, indicating that endothelial cells form a barrier mimicking the systemic delivery route of drugs to the heart. Conclusions Our systems are characterized by increased physiological accuracy and enable the study of hPSC-cardiomyocyte recovery and the effects of accumulated dose after multiple dosing, allowing individualized cardiotoxicity evaluation. In the future, we can further increase the complexity by including multi-organ-on-chip approaches, as for example heart-liver-on-chip to revolutionize the screening of therapeutic targets and the prediction of drug efficacy.

Hydrogel‐Sheathed Hipsc‐Derived Heart Microtissue Enables Anchor‐Free Contractile Force Measurement

Engineering Human Ventricular Heart Muscles Based on a Highly Efficient System for Purification of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes

Engineered Heart Tissues for Standard 96-Well Tissue Culture Plates

Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function

Micro‐Engineered Heart Tissues on‐Chip with Heterotypic Cell Composition Display Self‐Organization and Improved Cardiac Function

Simultaneous electromechanical monitoring in engineered heart tissues using a mesoscale framework

In vivo grafting of large engineered heart tissue patches for cardiac repair

A Platform for Assessing Cellular Contractile Function Based on Magnetic Manipulation of Magnetoresponsive Hydrogel Films

GelMA Micropattern Enhances Cardiomyocyte Organization, Maturation, and Contraction Via Contact Guidance.

Injectable carbon nanotube-functionalized hydrogel as a tool for cardiac tissue engineering

Design and fabrication of an integrated heart-on-a-chip platform for construction of cardiac tissue from human iPSC-derived cardiomyocytes and in situ evaluation of physiological function

A versatile high-throughput assay based on 3D ring-shaped cardiac tissues generated from human induced pluripotent stem cell derived cardiomyocytes

Abstract 16714: An Injectable Thermo-Responsive Hydrogel as a Tool for Cardiac Tissue Engineering Efforts: In vitro and in vivo Biocompatibility Assessment

Biohybrid 3D Printing of a Tissue‐Sensor Platform for Wireless, Real‐Time, and Continuous Monitoring of Drug‐Induced Cardiotoxicity

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

P4499Development of a hydrogel-based pre-vascularized 3D cardiac patch displaying capillary network

Abstract 368: Ex vivo Fabrication of Heart Tissue Model With Perfusable Blood Vessels Using Cell Sheet

Innovative models for cardiotoxicity assessment in human pluripotent stem cell-derived cardiomyocytes that enable clinically relevant treatment regimen

HiPSC-derived cardiomyocyte cultivation and measurement of electrophysiological properties on gelatine/glucose/polypyrrole scaffold

Construction of Thick Myocardial Tissue through Layered Seeding in Multi-Layer Nanofiber Scaffolds

Three-Dimensional Stretchable Sensor-Hydrogel Integrated Platform for Cardiomyocyte Culture and Mechanotransduction Monitoring